Board changes following
transformation to pure-play CDMO business model
Oxford, UK - 11 March 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or
"the Company"), a quality and innovation-led cell and gene therapy
CDMO, today announces that CDMO expert, Peter Soelkner, will join
the Board as a Non-Executive Director, effective from 15 March
2024. Concurrently, as part of Oxford Biomedica's transformation
into a pure-play CDMO, the Company announces that Catherine
Moukheibir and Dr. Michael Hayden have informed the Board that they
do not intend to stand for re-election at the upcoming Annual
General Meeting in June 2024. Dr. Michael Hayden will continue to
be an adviser to the Science and Technology Advisory
Committee.
Peter Soelkner has more than 30
years' experience in the global pharmaceutical services industry
with significant CDMO expertise. He is currently Managing Director
of Vetter Pharma, a global Aseptic Filling and Packaging CDMO,
where over the past 15 years he has helped grow revenues from $200
million to more than $1 billion. Prior to Vetter, Mr. Soelkner held
various senior positions at Sartorius including Vice President of
the Americas region where he expanded the global footprint of the
business across the US and multiple sectors. He has an MBA from
Columbia Business School, New York and Masters in Chemical
Engineering from TU Dortmund University, Germany.
Dr.
Roch Doliveux, Non-Executive Chairman of Oxford Biomedica,
commented: "Alongside OXB's
transformation to become a pure-play viral vector CDMO, the Board
of Directors has reviewed its breadth of skills and taken the
decision to streamline the Board whilst bolstering its CDMO
expertise. In light of this, we are delighted to welcome Peter
Soelkner given his impressive track record in significantly growing
Vetter, a leading global CDMO from $200m to more than $1bn in
revenues. In parallel, Catherine Moukheibir and Dr. Michael Hayden,
who have played a defining role in shaping OXB's new strategy, both
volunteered not to stand for re-election at
the next AGM given that their strengths lie more in therapeutics
rather than CDMO. I would like to personally thank Catherine and
Michael for their impeccable service, loyalty and valuable
insights."
Peter Soelkner commented: "I am
pleased to be joining this innovative, client-centric, global
business at such an exciting juncture in the Company's
journey.
In my view Oxford Biomedica is extremely well-positioned as a
pure-play CDMO and I am excited to apply my skillset and experience
to help deliver the strategy to clients, enabling them to deliver
life-changing therapies to patients."
Relevant disclosures
There are no disclosures required to
be made in accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica
plc:
Sophia Bolhassan, VP, Corporate Affairs and IR - T:
+44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led cell and gene therapy contract
development and manufacturing organisation (CDMO) with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original pioneers in cell
and gene therapy, the Company has more than 25 years of experience
in viral vectors; the driving force behind the majority of gene
therapies. The Company collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg,
France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.
